XML 41 R21.htm IDEA: XBRL DOCUMENT
v3.20.4

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Revenue from Significant Partners | Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
| Year-ended December 31,
| 2020 |  | 2019 |  | 2018
Partner A | 45 | % |  | 13 | % |  | 40 | %
Partner B | 17 | % |  | 27 | % |  | 13 | %
Partner C | < 10% |  | < 10% |  | 20 | %
* Except for Partner B, who represents the same customer for all three years presented, Partner A represents two different customers and Partner C represents another two different customers for the three years presented.
Schedule of Commercial License Rights | Commercial license and other economic rights consist of the following (in thousands):
|  | December 31, 2020 |  | December 31, 2019
|  | Gross |  | Adjustments(1) |  | Net |  | Gross |  | Adjustments(2) |  | Net
Aziyo and CorMatrix |  | $ | 17,696 |  |  | $ | (9,588) |  |  | $ | 8,108 |  |  | $ | 17,696 |  |  | $ | (5,500) |  |  | $ | 12,196 |
Palvella |  | 10,000 |  |  | (10,000) |  |  | — |  |  | 10,000 |  |  | (7,492) |  |  | 2,508 |
Selexis and Dianomi |  | 10,602 |  |  | (7,731) |  |  | 2,871 |  |  | 10,602 |  |  | (5,216) |  |  | 5,386 |
Total |  | $ | 38,298 |  |  | $ | (27,319) |  |  | $ | 10,979 |  |  | $ | 38,298 |  |  | $ | (18,208) |  |  | $ | 20,090 |
(1) Amounts represent accumulated amortization to principal or research and development expenses of $21.3 million and credit loss adjustments of $6.0 million as of December 31, 2020 . Of the $6.0 million credit loss adjustments as of December 31, 2020, $5.5 million was recorded to retained earnings upon the adoption of ASU 2016-13, Financial Instruments - Credit Losses, on January 1, 2020. (2) Amounts represent accumulated amortization to principal or research and development expenses as of December 31, 2019.
Schedule of Disaggregation of Revenue | Royalty revenue for 2020, 2019 and 2018 are reported as below (in thousands):
|  | Year ended December 31,
|  | 2020 |  | 2019 |  | 2018
Kyprolis |  | $ | 25,164 |  |  | $ | 25,046 |  |  | $ | 21,686 |
Evomela |  | 6,377 |  |  | 5,171 |  |  | 5,658 |
Other |  | 2,255 |  |  | 2,566 |  |  | 1,952 |
Promacta |  | N/A |  | 14,193 |  |  | 99,260 |
|  | $ | 33,796 |  |  | $ | 46,976 |  |  | $ | 128,556 |
The following table represents disaggregation of Material Sales and License fees, milestone and other (in thousands):
|  | Year ended December 31,
|  | 2020 |  | 2019 |  | 2018
Captisol |  | $ | 109,959 |  |  | $ | 31,489 |  |  | $ | 29,123 |
Contract |  |  |  |  |  |
Service Revenue |  | 21,803 |  |  | 16,776 |  |  | 4,749 |
License Fees |  | 4,378 |  |  | 6,199 |  |  | 78,195 |
Milestone |  | 11,516 |  |  | 17,173 |  |  | 6,577 |
Other |  | 4,967 |  |  | 1,669 |  |  | 4,253 |
|  | $ | 42,664 |  |  | $ | 41,817 |  |  | $ | 93,774 |
Schedule of Computation of Basic and Diluted Net Income (Loss) per Share | The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
Weighted average shares outstanding: | 16,185 |  |  | 18,995 |  |  | 21,160 |
Dilutive potential common shares: |  |  |  |  |
Restricted stock | — |  |  | 43 |  |  | 72 |
Stock options | — |  |  | 719 |  |  | 1,125 |
Warrants associated with 2019 Notes | — |  |  | — |  |  | 1,017 |
2019 Convertible Senior Notes | — |  |  | — |  |  | 693 |
Shares used to compute diluted income (loss) per share | 16,185 |  |  | 19,757 |  |  | 24,067 |
Potentially dilutive shares excluded from calculation due to anti-dilutive effect | 8,458 |  |  | 8,926 |  |  | 2,845 |

X
- Definition Schedule of Commercial License Rights [Table Text Block] + References No definition available. + Details
Name: | lgnd_ScheduleofCommercialLicenseRightsTableTextBlock
Namespace Prefix: | lgnd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration